Clinical trials: Acute Non-Lymphocytic Leukemia
Acute Myeloid Leukemia
A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia
This was an open-label pilot study that evaluated the safety and preliminary evidence of a therapeutic effect of dociparstat in conjunction with standard induction and consolidation therapy for acute myeloid leukemia (AML).
- Trial name
- PGX-AML (NCT02056782)
- Testing
- Dociparstat sodium
- Volunteers
- 12 people
- Sponsor
- Jazz Pharmaceuticals
Acute Myeloid Leukemia
D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients
With the aging of society, the incidence of elderly leukemia in China has been increasing year by year. The elderly patients with Acute Leukemia have poor basal state, and there are many important organ diseases such as heart…
- Trial name
- NCT04168138
- Testing
- rhTPO
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Huihan Wang
Chronic Myeloid Leukemia, Myelodysplastic Syndrome
Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) is an established form of treatment for hematological abnormalities. Poor graft function, occurs when there poor donor engraftment.
- Conditions
- Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia
- Trial name
- NCT02258490
- Testing
- G-CSF mobilized CD34+ selected cells for transplantation
- Where
- United States
- Sponsor
- Emory University
AML, Adult
Pharmacoscopy-guided Clinical Standard-of-care in r/r AML
With an overall survival of below 12 months, the outcome of relapsed/refractory AML (RR AML) is poor, making it a critical challenge to identify effective therapies at this stage.
- Trial name
- RAPID-01 (NCT06138990)
- Testing
- Pharmacoscopy, Clinical standard-of-care (physician's choice)
- Where
- 2 sites in Switzerland
- Volunteers
- 88 people
- Sponsor
- ETH Zurich
B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Long-term Follow up Local Registry Study of Kymriah in South Korea
This study is multicenter, primary data collection, non-interventional registry study to assess long-term safety, secondary malignancy risk, and effectiveness of tisagenlecleucel in patients with B-cell malignancies in a routine…
- Trial name
- NCT06785818
- Testing
- Tisagenlecleucel
- Where
- 18 sites in South Korea
- Volunteers
- 500 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
BeFluBu vs FluBuRux Conditioning in Haploidentical HCT
Haploidentical hematopoietic stem cell transplantation irrespective of the conditioning intensity and graft-versus-host disease prophylaxis is associated with high frequency of primary and secondary graft failure.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Lymphoblastic Lymphoma
- Trial name
- NCT06477549
- Testing
- Bendamustine Hydrochloride, Ruxolitinib
- Where
- Russia
- Volunteers
- 220 people
- Sponsor
- St. Petersburg State Pavlov Medical University
Acute Myeloid Leukemia (AML)
Assessing Refractoriness and Infectious Survival Events in AML
Despite therapeutic advance in acute myeloid leukemia (AML), the prognosis remains poor, with an overall survival (OS) of 30% at 5 years [1, 2].
- Trial name
- ARISE-AML (NCT06709235)
- Where
- France
- Volunteers
- 280 people
- Sponsor
- Hospices Civils de Lyon
Acute Myeloid Leukemia
Harnessing the Immunosuppressive Leukemic Microenvironment to Engineer T Cells With Enhanced Anti-tumor Functionality
This is a monocentric, retrospective and prospective study aimed to underline the potential of T-cell receptor (TCR)-mediated Ab recognition from the post transplant setting in acute myeloid leukemia (AML).
- Trial name
- SynT (NCT07743047)
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
AML, Acute Myeloid Leukemia
Cardioprotection in AML
Patients with acute myeloid leukemia (AML) often receive a drug called daunorubicin. Daunorubicin is a type of drug called an anthracycline, which increases the risk of some damage to the heart.
- Trial name
- AML 001 (NCT04977180)
- Testing
- Cardioprotection
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Virginia
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00935090
- Testing
- 3'-deoxy-3'-[18F]fluorothymidine
- Where
- United States
- Sponsor
- Barbara Ann Karmanos Cancer Institute
T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
Patients eligible for this study have a type of blood cancer called T-cell leukemia or lymphoma (lymph gland cancer). The body has different ways of fighting infection and disease. No one way seems perfect for fighting cancers.
- Conditions
- T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
- Trial name
- MAGENTA (NCT03081910)
- Testing
- Autologous CD5.CAR/28zeta CAR T cells, Allogeneic CD5.CAR/28zeta CAR T cells
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Baylor College of Medicine
Leukemia
Physical Activity in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
RATIONALE: Physical activity sessions may help improve physical function, quality of life, and symptoms caused by chemotherapy in older patients with acute myelogenous leukemia.
- Trial name
- NCT00554489
- Testing
- exercise intervention
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Wake Forest University Health Sciences
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes
Study CC-91633-AML-001 is a Phase 1, open-label, dose escalation and expansion, first-in-human (FIH) clinical study of CC-91633 (BMS-986397) in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in…
- Trial name
- NCT04951778
- Testing
- CC-91633
- Where
- 9 sites in United States, Spain
- Volunteers
- 56 people
- Sponsor
- Celgene
Acute Lymphoblastic Leukemia, B Cell Lymphoma
Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies
This is the second stage of the previous anti-CD19 CAR-T therapy (NCT02965092). The study aims to evaluate the safety and efficacy of consolidative allo-HSCT following CAR-T therapy in patients with relapsed or refractory B cell…
- Trial name
- NCT03366350
- Testing
- Allogeneic hematological stem cell transplantation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Wuhan Sian Medical Technology Co., Ltd
Chronic Myeloproliferative Disorders, Leukemia
A Standardized Nursing Intervention Protocol for HCT Patients
RATIONALE: Visiting patients at home to teach them about self care after a stem cell transplant may be more effective than standard therapy in improving quality of life.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00951626
- Testing
- exercise intervention, telephone-based intervention, dietary intervention
- Where
- United States
- Volunteers
- 282 people
- Sponsor
- City of Hope Medical Center
Acute Myeloid Leukemia and Myelodysplastic Syndrome
Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
The purpose of the study is to determine the safety and benefit of nivolumab, ipilimumab or the combination of nivolumab with ipilimumab given after bone marrow transplant for patients with acute myelogenous leukemia and…
- Trial name
- CPIT-002 (NCT02846376)
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Hackensack Meridian Health
Adult Patients With Adverse Risk Acute Myeloblastic Leukemia
Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)
To search for a Maximum Tolerated Dose (MTD) for the combination of daratumumab and induction chemotherapy with Idarubicin and cytarabine or CPX-351 in patients with Acute Myeloblastic Leukemia (AML) of poor prognosis
- Trial name
- DARALAM (NCT05749276)
- Testing
- Darzalex
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Nantes University Hospital
AML, Adult
Novel Approaches to Target MECOM/EVI1 in AML
This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.
- Trial name
- NCT05839392
- Testing
- Biological characterization of AML with MECOM or atypical 3q26 rearrangements
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Leukemia, Myelodysplastic Syndromes
Genetic Study of Children With Soft Tissue Sarcoma or Rhabdomyosarcoma
RATIONALE: Determination of genetic markers for soft tissue sarcoma or rhabdomyosarcoma may help doctors identify patients who are at risk for therapy-related leukemia.
- Conditions
- Leukemia, Myelodysplastic Syndromes, Sarcoma
- Trial name
- NCT00003793
- Testing
- clonality analysis, microsatellite instability analysis, mutation analysis
- Where
- 96 sites in United States, Australia and 1 more
- Volunteers
- 294 people
- Sponsor
- Children's Oncology Group
Acute Leukemia, Myeloid Leukemia
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
This is a multicenter, open-label study in people aged 18 and older with relapsed or refractory acute myeloid leukemia. It has two parts.
- Conditions
- Acute Leukemia, Myeloid Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT07157514
- Testing
- 131I-apamistamab, Fludarabine, Cyclophosphamide
- Volunteers
- 306 people
- Sponsor
- Actinium Pharmaceuticals